Enanta Pharmaceuticals (ENTA) Research & Development (2012 - 2026)

Enanta Pharmaceuticals' Research & Development history runs 15 years deep, the most recent figure standing at $19.4 million for Q1 2026.

• Quarterly Research & Development fell 30.72% year-over-year to $19.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $91.3 million (down 20.76% YoY) and the FY2025 annual result came in at $106.7 million, down 18.81% from the prior year.
• Research & Development was $19.4 million for Q1 2026 at Enanta Pharmaceuticals, down from $20.9 million in the prior quarter.
• Across five years, Research & Development topped out at $43.5 million in Q1 2023 and bottomed at $19.4 million in Q1 2026.
• A 5-year average of $32.8 million and a median of $34.8 million in 2022 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2023 — Research & Development gained 9.97% — and 2024, when it slumped 33.14%.
• Enanta Pharmaceuticals' Research & Development stood at $40.9 million in 2022, then slipped by 11.08% to $36.4 million in 2023, then retreated by 23.96% to $27.7 million in 2024, then declined by 24.58% to $20.9 million in 2025, then fell by 6.79% to $19.4 million in 2026.
• Business Quant data shows ENTA's Research & Development at $19.4 million in Q1 2026, $20.9 million in Q4 2025, and $23.8 million in Q3 2025.